Sanofi’s Board of Directors proposes the appointment of Carole Ferrand, Emile Voest and Antoine
yver
as independent directors
Paris
,
the
February 22, 2022
. During its meeting of February 22, 2022, Sanofi’s Board of Directors decided to propose, within the framework of the next General Meeting of Shareholders scheduled for May 3, 2022, the renewal of the terms of office of Paul Hudson, Christophe Babule, Patrick Kron and Gilles Schnepp and the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent directors. Melanie Lee and Carole Piwnica leave the Council. The President thanked Carole Piwnica for her contribution to the transformation of the group during her almost 12 years of mandate, and Melanie Lee for her contribution to the scientific reorientation of the group and the creation of the Scientific Committee.
Carole Ferrand
is currently Chief Financial Officer of the Capgemini group and director of Fnac Darty. She began her career in 1992 at PricewaterhouseCoopers, where she held auditing and then financial advisory positions. After ten years at Sony France as Chief Financial Officer (2000-2002), then General Secretary, she was appointed Chief Financial Officer of the Europacorp group in 2011. In 2013, Carole Ferrand was appointed Chief Financial Officer of the Artémis group. She then sat on the Capgemini Board of Directors for two years (2016-2018) before being appointed to her current position as Group Chief Financial Officer.
Carole Ferrand is a graduate of the Ecole des Hautes Etudes Commerciales (HEC Paris).
Emile Voest
is currently a trustee of Cancer Core Europe, a collaboration between seven leading comprehensive cancer centers in Europe, and was Executive Medical Director of the Netherlands Cancer Institute (NKI) until 2021. He is Professor of Medical Oncology at Utrecht University (UMC) since 1999 and leads a research group at NKI and the Oncode Institute. He founded and directs several innovative projects in precision oncology. He is a co-founder and non-executive member of the Board of Trustees of the Hartwig Medical Foundation (specializing in large-scale DNA analysis), a member of the Board of Trustees of the Center for Personalized Cancer Treatment and leads several innovative clinical trials in precision oncology. In recent years, he has also held various leadership positions in medical organizations such as ESMO and ASCO.
Emile Voest holds a doctorate in medicine from the University of Utrecht.
Anthony
yver
has been in charge of the development of Centessa Pharmaceuticals, Inc. since 2021. He began his career in oncology at Rhône Poulenc Rorer Inc. in 1990. In 1999, he joined the Aventis group as Senior Director of Global Clinical Development in Oncology. In 2005, he was appointed Senior Director of Oncology Development at Johnson & Johnson and, in 2006, Executive Director of the Oncology Department at Schering-Plough. From 2009 to 2016, he led the global oncology development of AstraZeneca and notably developed the TAGRISSO and LYNPARZA treatments. In particular, he held the position of Senior Vice President in charge of Oncology and China Development of AstraZeneca from 2013-2016. Subsequently, he was appointed Executive Vice President of Oncology Research and Development at Daiichi Sankyo, and notably developed the ENHERTU treatment.
Antoine Yver, former intern in medicine at the Paris Hospitals (AAIHP) and former assistant clinical director in Paris, graduated in medicine and pediatrics from the University of Paris-Saclay. He also holds a Master’s degree in immunology from the University of Paris.
Serge Weinberg
Chairman of the Board of Directors
“
These changes correspond to the Board’s desire to strengthen the scientific skills, particularly in oncology, and financial skills of the Board, while maintaining the size of the Board at 1
6
members
(
there
including the
2
salaried directors)
.”
The composition of the Board’s specialized committees will be reviewed at the end of the General Meeting of Shareholders scheduled for May 3, 2022.
AT
in relation to
Sanofi
We are an innovative, global health company driven by one purpose: to pursue the miracles of science to improve people’s lives. Our teams, present in a hundred countries, are working to transform the practice of medicine to make the impossible possible. We provide therapeutic solutions that can change the lives of patients and vaccines that protect millions of people around the world, guided by the ambition of sustainable development and our social responsibility.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media relations
Sally Bath
| + 1 617 834 6026 |
Nicholas Obrist
| + 33 6 77 21 27 55 |
Victor Rouault
| + 33 6 70 93 71 40 |
Investor Relations
Eva Schaefer-Jansen
| + 33 7 86 80 56 39 | [email protected]
Arnaud
Delepine
| + 33 6 73 69 36 93 | [email protected]
Corentine Driancourt
| + 33 6 40 56 92 21 | [email protected]
Felix Lauscher
| + 1 908 612 7239 | [email protected]
Priya Nanduri
| +1 908 981 5560 | [email protected]
Nathalie Pham
| + 33 7 85 93 30 17 | [email protected]
Attachment